Transcriptional Activity of Heat Shock Factor 1 at 37 oC Is Repressed through Phosphorylation on Two Distinct Serine Residues by Glycogen Synthase Kinase 3alpha and Protein Kinases Calpha and Czeta *

Boyang ChuDagger §, Rong ZhongDagger , Fabrice Soncinparallel , Mary Ann StevensonDagger , and Stuart K. CalderwoodDagger **

From the Dagger  Department of Adult Oncology, Dana Farber Cancer Institute and Joint Center for Radiation Therapy, Harvard Medical School, Boston, Massachusetts 02115 and the parallel  CNRS EP 560, Institut Pasteur de Lille, 1 Rue Calmette-BP 245, 59021 Lille Cedex, France

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Heat shock factor 1 (HSF1) is the key transcriptional regulator of the heat shock genes that protect cells from environmental stress. However, because heat shock gene expression is deleterious to growth and development, we have examined mechanisms for HSF1 repression at growth temperatures, focusing on the role of phosphorylation. Mitogen-activated protein kinases (MAPKs) of the ERK family phosphorylate HSF1 and represses transcriptional function. The mechanism of repression involves initial phosphorylation by MAP kinase on serine 307, which primes HSF1 for secondary phosphorylation by glycogen synthase kinase 3 on a key residue in repression (serine 303). In vivo expression of glycogen synthase kinase 3 (alpha  or beta ) thus represses HSF1 through phosphorylation of serine 303. HSF1 is also phosphorylated by MAPK in vitro on a second residue (serine 363) adjacent to activation domain 1, and this residue is additionally phosphorylated by protein kinase C. In vivo, HSF1 is repressed through phosphorylation of this residue by protein kinase Calpha or -zeta but not MAPK. Regulation at 37 °C, therefore, involves the action of three protein kinase cascades that repress HSF1 through phosphorylation of serine residues 303, 307, and 363 and may promote growth by suppressing the heat shock response.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Exposure of cells to elevated temperatures leads to the expression of the heat shock response, in which the induction of a cohort of heat shock proteins (HSPs)1 is accompanied by the expression of heat resistance (1, 2). In mammalian cells, HSP genes are regulated at the transcriptional level by heat shock factor 1 (HSF1), a sequence-specific transcription factor that interacts with heat shock elements (HSEs) in their promoters (3-5). Much evidence now suggests that although HSPs protect cells during hyperthermia, growth of cells under nonstress conditions is incompatible with the expression of the heat shock response (6). Heat shock arrests cells in G1 (7, 8), and HSF1 expression delays the progression of cells through G1,2 whereas HSP70 overexpression inhibits growth and development (6, 9). In addition, HSF1 represses the ability of Ras protein to activate the promoters of immediate early genes such as c-fos (10). There evidently exists, however, a well-conserved mechanism to inhibit the activity of HSF1 at 37 °C and prevent these deleterious effects on cell growth. We have examined molecular mechanisms involved in the repression of HSF1 by signaling pathways involved in growth regulation.

Activation of HSF1 involves the conversion of HSF1 from a latent cytoplasmic monomer to a trimeric nuclear protein complex that controls the transcription of heat shock genes (3-5, 11) Trimerization is governed by arrays of amphipathic alpha  helical residues ("leucine zippers") in the N-terminal domain and is negatively regulated by a fourth such domain in the C terminus (3, 12). However, although necessary, nuclear localization and DNA binding are not sufficient for the full transcriptional competence of HSF1, which can be activated to an intermediate state in which it binds to HSE sequences but does not stimulate transcription (13-16). Much evidence suggests a role for phosphorylation in the conversion of HSF1 from this intermediate state into a transcriptionally active form (13, 14, 16, 17). In addition, HSF from yeast and HSF1 from mammalian cells both undergo hyperphosphorylation during heat shock, and their hyperphosphorylation correlates well with transcriptional activation (17-19). Our previous studies showed that HSF1 is phosphorylated at multiple sites mostly on serine residues and that mitogen-activated protein kinases (MAPKs) of the ERK-1 family phosphorylate HSF1 on serine and repress the transcriptional activation of the heat shock protein 70B (HSP70B) promoter by HSF1 in vivo (20). These experiments and a number of other reports thus indicate that HSF1 is antagonized by Ras-MAPK signaling and that this may be a mechanism for HSF1 repression at 37 °C (20-24). The repressive effects of MAPK were transmitted through a specific serine residue (Ser-303) in a proline-rich sequence within the transcriptional regulatory domain of human HSF1 (20). However, despite the importance of Ser-303 in transmitting the signal from the MAPK cascade to HSP70 transcription, there was no evidence that Ser-303 could be phosphorylated by MAPK in vitro, although an adjacent residue (Ser-307) was avidly phosphorylated by MAPK (20). Preliminary studies suggested that Ser-303 is phosphorylated by glycogen synthase kinase 3 (GSK3) through a mechanism dependent on primary phosphorylation of Ser-307 by MAPK (20). In the present experiments, we have demonstrated the sequential phosphorylation by MAPK and GSK3 and its role in HSF1 repression.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Cell Culture-- NIH 3T3 cells were grown to confluence in Dulbecco's modified Eagle's medium containing 10% bovine calf serum and passaged at a 1/10 ratio.

Site-directed Mutagenesis, Expression, and Purification of Recombinant HSF1-- Oligonucleotide-directed mutagenesis was performed using the pALTER-1 vector as described previously (20). Following mutation, DNA sequences were checked by dideoxynucleotide sequencing and cloned into the pcDNA3.1 vector for mammalian expression and into the pET22B vector for expression in Escherichia coli. For purification, wild-type human HSF1 cDNA and point-mutated forms S303G, S307G, and S363G (25) were induced in E. coli by isopropyl-1-thio-beta -D-galactopyranoside treatment, extracted, and purified to homogeneity as described (26).

In Vitro Phosphorylation of Recombinant HSF1-- Purified MAPK from P. ochraceus (p44mpk), PKCalpha from rabbit brain and GSK3alpha , mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP K2), and pp90rsk S6 kinase isoform RSK2 from rabbit muscle were obtained from Upstate Biotechnology (Lake Placid, NY). In vitro phosphorylation of HSF1 by MAP kinase and GSK3 was carried out as described previously (20). Purified enzymes (MAPK and GSK3alpha ) were tested for contamination with other kinases that might phosphorylate HSF1 by assaying with peptides specific for MAPKAP K2, RSK2, and PKCalpha . RSK2 activity was assayed as described using substrate peptide RRRLSSRA, utilizing purified RSK2 enzyme as a positive control (27). Assays were carried out with or without MAPK addition, because MAPK is a potent activator of RSK2. MAPKAP K2 activity in the GSK3alpha preparation (with or without the addition of MAPK) was assayed as for RSK2 using MAPKAP K2 substrate peptide (KKLNRTLSVA) (28). Peptides were purified to greater than 90% by high performance liquid chromatography. Neither the MAPK nor GSK3alpha preparation was significantly contaminated with MAPKAP K2, RSK2, or PKCalpha . HSF1 can also be phosphorylated in vitro with casein kinase 2 and calmodulin kinase II; however, the phosphopeptide maps obtained from HSF1 treated with either enzyme were completely different from the MAPK or GSK3alpha maps (data not shown), indicating that HSF1 phosphorylation with MAPK or GSK3alpha does not reflect contamination with either casein kinase 2 or calmodulin kinase II. To phosphorylate HSF1 with PKCalpha , 5 µg of HSF1 was incubated with enzyme (25 ng), phosphatidylserine (100 µg/ml), CaCl2 (1 mM), ATP (5 µM), and 32P-labeled ATP (1 µCi/µl) in buffer (20 mM HEPES, pH 7.4, 10 mM MgCl2, and 0.2 mM EGTA) to a final volume of 50 µl. Incubations were for 12 min at 25 °C. Protein kinase C activity was assayed using the peptide QKRPSQRSKYL.

Two-dimensional-Phosphopeptide Mapping and Peptide Sequencing-- Two-dimensional phosphopeptide mapping was carried out after digestion with trypsin as described previously (20, 28). For sequencing, peptides were eluted from the TLC medium and subjected to multiple cycles of Edman degradation, and amino acids were identified by high performance liquid chromatography elution time (29). Sequencing was performed by the Biopolymer Laboratory, Brigham & Women's Hospital, Boston, MA.

Electrophoretic Mobility Shift Assay for HSF1-HSE Binding-- Binding of rHSF1 or nuclear HSF1 to HSE was assayed by electrophoretic mobility shift assay as described previously (14, 30).

Transfection-- HSF1 constructs were co-transfected with the chloramphenicol acetyltransferase (CAT) construct p2500CAT, which contains 2.5 kilobase pairs of 5'-noncoding sequence from the heat-inducible human HSP70B gene (31) (StressGen, Victoria, British Columbia, Canada). Cells were seeded at a density of 250,000 per 100-mm tissue culture dish 24 h prior to transfection carried out using calcium phosphate precipitation according to the manufacturer's protocol (Promega). Cells were harvested 48 h after incubation with plasmids for assay of CAT protein expression (20). To control for transfection efficiency, cells were co-transfected with pCMV-beta -galactosidase plasmid and assayed for beta -galactosidase as described (10). In some experiments, HSF1 was co-transfected with MEK-1 expression vector (pCMV-MKK-1) from Dr. N. G. Ahn (University of Colorado, Boulder, CO) (32). For GSK3 plasmids pMT2GSK3alpha and pMT2GSK3beta (33), we thank Dr. J. R. Woodgett (Ontario Cancer Institute), and for pPKCalpha and pPKCzeta expression plasmids and purified recombinant hGSK3beta , we thank Dr. B. Price, Dana Farber Cancer Institute (Boston, MA).

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

In order to investigate the hypothesis that HSF1 is phosphorylated on the key regulatory serine residue 303 by GSK3 only after a priming phosphorylation by MAPK, we first examined the effect of mutating serines 303 and 307 on sequential phosphorylation by MAPK and GSK3 (Fig. 1). Wild-type recombinant HSF1 (wtHSF1) was not phosphorylated by recombinant GSK3beta (Fig 1, lane 3) as shown previously with purified rabbit GSK3beta (20) but was phosphorylated by purified GSK3alpha (lane 2). MAPK phosphorylated wtHSF1 (Fig. 1, lane 1) and led to a marked increase in phosphorylation by GSK3alpha and -beta (lanes 4 and 5). When similar experiments were carried out on HSF1 with a serine to glycine mutation (S303G), the levels of phosphorylation in incubations with MAPK, GSK3alpha , and GSK3beta were similar to those in the wt control when used individually. (Fig. 1, lanes 6-8). However, we did not observe increased phosphorylation by GSK3alpha and -beta when combined with MAPK (lanes 9 and 10). Thus, inactivation of the putative GSK3 site (Ser-303) prevents MAPK stimulation of HSF1 phosphorylation by GSK3 (Fig. 1). The phosphorylation of HSF1 observed with GSK3alpha alone, without MAPK priming, is evidently at residues other than Ser-303 as similar levels of 32P uptake were observed in wtHSF1 and S303G when incubated with GSK3alpha (Fig. 1, lanes 2 and 7). Substitution of glycine for serine at Ser-307 (S307G) led to a HSF1 with similar properties to S303G, with phosphorylation by MAPK and GSK3alpha (Fig. 1, lanes 11 and 12), but no stimulation of GSK3 induced phosphorylation by MAPK (lanes 14 and 15); this indicates a requirement for intact Ser-307 and MAPK for GSK3 phosphorylation of HSF1 at Ser-303, consistent with a priming role for MAPK in HSF1 regulation by GSK3 (20). The experiments also show that despite loss of the phosphorylation site at serine 307, S307G is still phosphorylated by MAPK (lane 11). This is, however, consistent with previous studies indicating two major MAPK sites on HSF1 (Fig. 1; Ref. 20).


View larger version (45K):
[in this window]
[in a new window]
 
Fig. 1.   Phosphorylation of HSF1 by MAPK and GSK3 in vitro. Recombinant wtHSF1, S303G, or S307G was incubated with MAPK (p44mpk), GSK3alpha , or GSK3beta either singly or sequentially in the presence of [gamma -32P]ATP. Incubations were terminated by boiling in SDS-polyacrylamide gel electrophoresis sample buffer, and phosphoproteins were analyzed by 10% SDS-polyacrylamide gel electrophoresis and autoradiography. For sequential treatment, HSF1 was preincubated with MAPK prior to incubation with GSK3alpha or GSK3beta as described under "Materials and Methods." wtHSF1 was incubated with MAPK alone (lane 1), GSK3alpha alone (lane 2), GSK3beta alone (lane 3), MAPK + GSK3alpha (lane 4), or MAPK + GSK3beta (lane 5). S303G was incubated with MAPK alone (lane 6), GSK3alpha alone (lane 7), GSK3beta alone (lane 8), MAPK + GSK3alpha (lane 9), or MAPK + GSK3beta (lane 10). S307G was incubated with MAPK alone (lane 11), GSK3alpha alone (lane 12), GSK3beta alone (lane 13), MAPK + GSK3alpha (lane 14), or MAPK + GSK3beta (lane 15). For controls, HSF1 (lane 16), S303G (lane 17), and S307G (lane 18) were incubated with [gamma -32P]ATP in the absence of protein kinases. In lane 19, MAPK, GSK3alpha , and GSK3beta were incubated together without added HSF1 in the presence of [gamma -32P]ATP.


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 2.   Hierarchical phosphorylation of HSF1 by MAPK and GSK3. A, two-dimensional phosphopeptide map of recombinant HSF1 after treatment with MAPK (p44mpk) in vitro. HSF1 was incubated with MAPK and [gamma -32P]ATP, isolated, and subjected to tryptic two-dimensional phosphopeptide mapping as described under "Materials and Methods." B, HSF1 was incubated sequentially with p44mpk and GSK3alpha in the presence of [gamma -32P]ATP and subjected to two-dimensional mapping as in A. C, HSF1 mutant protein S307G was incubated with p44mpk and GSK3alpha in the presence of [gamma -32P]ATP and subjected to two-dimensional mapping as in B. D, HSF1 mutant protein S303G was incubated with p44mpk and GSK3alpha in the presence of [gamma -32P]ATP and subjected to two-dimensional mapping as in C.

In order to confirm that the changes in levels of 32P incorporation observed in HSF1 treated sequentially with MAPK and GSK3alpha (Fig. 1) were due to hierarchical phosphorylation, we examined the relative levels of phosphorylation of Ser-303 and Ser-307 using tryptic two-dimensional phosphopeptide mapping (Fig. 2). We used GSK3alpha in this study due to its more ready availability. Incubation of HSF1 with purified MAPK in vitro followed by two-dimensional mapping led to the resolution of two major phosphopeptides (Fig. 2A, a and b) as shown previously (20). A number of minor spots were also seen. Two of these, which occur at positions to the left of spots a and b in Fig. 2, were observed in most experiments and may correspond to higher phosphorylated forms of peptides a and b, with similar hydrophobicity to a and b but with lower electrophoretic mobility due to their greater negative charge (28). The spots closer to the origin were not observed consistently and may be products of incomplete digestion or minor phosphorylation (Fig. 1A). Although incubation in vitro with GSK3alpha did lead to phosphorylation of HSF1 on residues other than Ser-303 (Fig. 1), no clear spots were resolved by two-dimensional mapping (not shown). Treatment of HSF1 with GSK3alpha after preincubation with MAPK led to increased phosphorylation (Fig. 1) and caused the appearance of a new spot (spot c) and the concomitant depletion of spot a (Fig. 2B). These experiments therefore suggest that spot c is produced through the phosphorylation by GSK3alpha of the polypeptide sequence in HSF1 that migrates as spot a and that the resulting spot (c) is retarded in the electrophoretic field (relative to a) due to the increase in negative charge resulting from double phosphorylation of this sequence (Fig. 2B). A previous study using purified rabbit GSK3beta had indicated the phosphorylation of HSF1 on four sites in addition to peptide c (phosphopeptides w, x, y, and z) by GSK3beta (20). This appeared to be due to contamination of the GSK3beta used in that study with another kinase (MAPKAP K2), which is activated by MAP kinase. We have subsequently shown that highly purified MAPKAP K2 phosphorylates HSF1 on sites w-z and that purified rabbit GSK3alpha and human recombinant GSK3beta , which are both free of MAPKAP K2 contamination, do not (data not shown). Our previous studies showed that the peptide that migrates to form spot a comprises amino acids 299-309 (EEPPSPPQSPR), containing sites at position 307 for MAPK phosphotransferase activity and a potential site at position 303 for GSK3 (20). Spot a thus consists of amino acids 299-309 singly phosphorylated at Ser-307, and it is predicted that spot c is doubly phosphorylated, at Ser-307 by MAPK and at Ser-303 by GSK3alpha . Mutation of Ser-307 to glycine (S307G) abolished both spot a and spot c after serial treatment with MAPK and GSK3alpha (Fig. 2C). Mutation of HSF1 at Ser-303 (S303G) abolished the appearance of spot c and prevented the depletion of spot a after serial phosphorylation, indicating that spot c is the product of double phosphorylation by MAPK and GSK3alpha and that Ser-303 is phosphorylated by GSK3alpha (Fig. 2D). These experiments are consistent with the hypothesis of primary phosphorylation of HSF1 on Ser-307 being a prerequisite for secondary phosphorylation on Ser by GSK3alpha .

We next examined the potential role of GSK3 in the regulation of HSF1 activity in vivo. We used a system described previously in which HSF1 expression from the pcDNA3.1.HSF1 (pHSF1) vector activates a heat shock promoter reporter construct in the absence of heat shock (20, 30, 31). HSF1 expression strongly induced HSP70B promoter activity in NIH3T3 cells, whereas co-expression of a GSK3alpha expression vector repressed the effects of HSF1 by 80%, and co-expression of pMEK-1, which increases cellular MEK-1 levels and specifically activates ERK1 and ERK2 (20), further reduced activity (Fig. 3). Similar results were obtained with a GSK3beta expression vector (not shown). When similar experiments were carried out using HSF1 mutant S303G, we found that repression of HSP70B promoter activity by GSK3alpha was effectively abolished, identifying serine 303 as the target for HSF1 repression by GSK3alpha in vivo (Fig. 3). Neither mutation of HSF1 at Ser-303 or Ser-307 nor treatment with GSK3alpha or MAPK affected the binding of HSF1 to heat shock elements, indicating that the effects observed are exerted downstream of DNA binding, at the level of transcriptional transactivation (20) (see Fig. 7). However, Ser-303 mutation did not completely block the repression of HSF1 by MEK1, suggesting further effects of MAPK on HSF1 function (Fig. 3).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of high-level expression of GSK3alpha on activation of the HSP70B promoter by HSF1. NIH-3T3 cells were transfected with p2500CAT (12 µg) alone or with expression plasmids pHSF1 (2 µg), pS303G (2 µg), pGSK3alpha (4 µg), or pMEK-1 (4 µg) as indicated. Each culture was also co-transfected with control plasmid pCMVbeta GAL (2 µg). Incubations and assays for CAT or beta -galactosidase were carried out as described under "Materials and Methods." CAT activity was indexed to beta -galactosidase activity to control for transfection efficiency, and results were then expressed as a percentage of the activity in cells co-transfected with p2500CAT and pHSF1 (first column). Experiments were carried out twice, and representative results are shown. At the plasmid concentrations used in these experiments, wild-type HSF1 and S303G expression vectors were equally effective in activation of the HSP70B promoter.

Because the data in Fig. 3 suggest that MAPK exerts repressive effects on HSF1 in addition to those mediated through Ser-303, we next analyzed the second major site on HSF1 phosphorylated by MAPK in vitro. We showed in Fig. 1A that two major phosphopeptides, a and b, are resolved in HSF1 after MAPK treatment in vitro. Phosphopeptide a contains serines 303 and 307 (Fig. 1). Analysis of phosphopeptide b isolated from the TLC plates after two-dimensional mapping indicated a sequence correspond to amino acids 362-372 in the human HSF1 sequence (25). To confirm this finding, we carried out site-directed mutagenesis on serine 363 contained within phosphopeptide b, which forms part of a sequence (PPSP) that conforms to a MAPK consensus motif (PX(S*/T*)P (where the asterisk indicates the phosphorylation of a threonine or serine residue (34-36)). Mutation of Ser-363 to alanine, to create S363A, had a profound effect on the phosphopeptide map of HSF1 after MAPK phosphorylation and major spot b was eliminated (although a faint spot was detected in some experiments) (Fig. 4). The peptide sequence contains other serine/threonine residues (notably, amino acids 368 and 369) within a proline-rich region that could potentially be phosphorylated at a low rate by MAPK. These experiments implicate Ser-363 as the second residue in HSF1 that undergoes phosphorylation after treatment with MAPK in vitro. To investigate the functional importance of Ser-363, we next examined the ability of MEK-1 expression to repress transcriptional activation of the HSP70B promoter by the S363A mutant (Fig. 5). Contrary to expectations, although Ser-363 is avidly phosphorylated by MAPK in vitro (Figs. 1 and 4), the S363A mutant was equally sensitive to MEK-1 repression compared with the wt control (Fig. 5). Thus, either Ser-363 phosphorylation does not affect the transcriptional activity of HSF1 or this site is not phosphorylated by MAPK in vivo. This region in HSF1 (360-365; RPPSPP) contains overlapping consensus motifs for both MAPK (PXS*/T*P) and PKC (RXXS*/T*) (36). We therefore examined the effect of expressing two isoforms of protein kinase C (PKCalpha and PKCzeta ) on the activities of co-transfected wtHSF1 and S363A (37). Recent studies have shown the existence of at least 11 PKC family members, which belong to three distinct classes based on structure and responsiveness to activators: PKC isoforms alpha , beta 1, beta II, and gamma  are Ca2+- and phorbol ester-dependent; PKC isoforms delta , epsilon , eta , and theta  require phorbol esters but are Ca2+-independent; and the atypical isoforms zeta  and lambda  require neither activator (38, 39). We chose PKCalpha and PKCzeta as representative members of the family, ranging from the "classical" Ca2+- and phorbol ester-dependent PKCalpha to the atypical PKCzeta , which is dependent on neither factor (37, 38). The transcriptional activity of wtHSF1 was inhibited by overexpression of MEK1, PKCalpha , or PKCzeta (Fig. 5). One explanation for this finding could be that PKC acts indirectly through upstream activation of MAPK family members ERK1 and ERK2 (40). However, on examining the effects of S363A mutation on responses to PKC expression, we found that although it is not involved in inhibition by MEK1, S363A substitution prevented repression of HSF1 activity caused by high level expression of PKCalpha or PKCzeta (Fig. 5). Mutation of HSF1 in the 303 position (S303G) did not, however, prevent HSF1 repression in cells overexpressing PKCalpha , indicating that the effects of PKC are exerted either directly or indirectly through phosphorylation of Ser-363 and do not involve Ser-303 (Fig. 6). To further probe the potential effects of PKC on HSF1 activity, we used calphostin C, which binds to the regulatory domain of PKC isoforms and specifically inhibits their activity (41). Incubation of cells co-transfected with pHSF1 and pPKCalpha with calphostin C partially restored HSF1 activity, further implying a role for PKCalpha in HSF1 repression (Fig. 6). However, incubation with calphostin C did not markedly enhance HSF1 activity in the absence of PKCalpha co-transfection in these cells (Fig. 6). Thus, Ser-363, although avidly phosphorylated by purified MAPK in vitro, is not a major target for MAPK in vivo but instead mediates HSF1 regulation by members of the PKC family (Figs. 5 and 6). We next determined whether HSF1 is directly phosphorylated by PKCalpha (Fig. 7). Recombinant HSF1 was phosphorylated by PKCalpha in vitro, whereas the phosphorylation of purified S363A under identical conditions was markedly reduced, suggesting that Ser-363 is phosphorylated by PKCalpha and directly mediates the effects of PKC expression on the transcriptional activity of HSF1 (Figs. 6 and 7).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of mutation of serine 363 on HSF1 phosphorylation by MAPK. Tryptic two-dimensional phosphopeptide map of recombinant S363A protein after treatment with MAPK (p44mpk) as described under "Materials and Methods."


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 5.   Effects of HSF1 mutation at Ser-363 on repression by MEK-1, PKCalpha , and PKCzeta expression. Cells were transfected with p2500CAT (12 µg), either without co-transfection or with pHSF1 (2 µg) or pS363A (2 µg). Effects of high level expression of protein kinase MEK-1, PKCalpha , or PKCzeta were examined by co-expression with pMEK-1 (4 µg), pPKCalpha (4 µg), or PKCzeta (4 µg), as indicated. Experimental conditions, assays, replication, and data analysis were as in Fig. 3. At the plasmid concentrations used here, wtHSF1 and S363A expression vectors were of similar effectiveness in activation of the HSP70B promoter, although at lower plasmid concentrations, S363A was slightly more effective.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 6.   Effects of mutation on serines 303 and 363 and exposure of cells to PKC inhibitor calphostin C on HSF1 repression by PKCalpha . Cells were transfected with p2500CAT (12 µg), either without co-transfection or with pHSF1 (2 µg), pS363A (2 µg), or pS303G (2 µg). Effects of PKCalpha expression were examined by co-expression with pPKCalpha (4 µg) as indicated. Calphostin C (50 nM) was added to controls and to cultures transfected with HSF1 alone or HSF1 + PKCalpha as shown in the figure. HSF1 transfectants, experimental conditions, assays, replication, and data analysis were carried out as in Fig. 3.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 7.   Phosphorylation of HSF1 by PKCalpha in vitro. Recombinant wtHSF1 or S363A was incubated with PKCalpha and [gamma -32P]ATP as described under "Materials and Methods." Incubations were terminated by boiling in SDS-polyacrylamide gel electrophoresis sample buffer, and phosphoproteins were analyzed by 10% SDS-polyacrylamide gel electrophoresis and autoradiography. For a positive control, wtHSF1 was incubated with MAPK as in Fig. 1.

Finally, in order to examine the effects of GSK3alpha and PKCalpha expression on the ability of HSF1 to form nuclear trimers capable of binding to heat shock elements, we carried out electrophoretic mobility shift assay analysis on nuclear extracts from control cells and transfectants (Fig. 8). HSF1 expression (Fig. 8, lane 5) led to the formation of a complex of similar electrophoretic mobility to HSF1-HSE complexes from heat shocked cells (Fig. 8, lanes 2 and 3). It is notable that although HSF1 expression increases activity of the HSP70B promoter by at least 100-fold, activation of HSF1-HSE binding increases only 2-3-fold in the transfectants (Figs. 3 and 7). This reflects the efficiency of transfection in the system used here (0.5-1.0%). Thus, increases in HSF1 binding in the transfectants are diluted by the 100-fold excess of untransfected cells. The trans-activation assay reports only on cells that have been co-transfected with HSF1 expression plasmid and the HSP70B promoter reporter construct and is unaffected by the presence of untransfected cells. Co-expression of GSK3alpha and PKCalpha did not inhibit the formation of the HSF1-HSE complex (Fig. 8, lanes 6 and 7). Thus, overexpression of these protein kinases represses HSF1 activity at step other than formation of DNA binding nuclear trimers.


View larger version (72K):
[in this window]
[in a new window]
 
Fig. 8.   HSE binding activity in NIH 3T3 cells after high level expression of HSF1, either alone or with GSK3alpha or PKCalpha . Cells were transfected with empty expression vector pcDNA3.1- (lane 4), with pHSF1 alone (lane 5), with pHSF1 + pGSK3alpha (lane 6), or with pHSF1 + pPKCalpha (lane 7). Nuclear extracts were prepared after 24 h of incubation with plasmids, and electrophoretic mobility shift assay analysis was carried out using a 32P-labeled consensus HSE from the HSP70B promoter. In control lane 1, no nuclear extract was added to the incubations. Lanes 2 and 3 are positive control samples from heat shocked NIH3T3 cells and heat shocked human K562 cells.

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

These experiments demonstrate that HSF1 is phosphorylated by GSK3alpha on a residue (Ser-303) within the transcriptional regulatory domain (Fig. 1) (42, 43). In addition, HSF1 phosphorylation at Ser-303 by GSK3alpha was dependent on HSF1 phosphorylation by MAPK on an adjacent residue (Ser-307) (Figs. 1 and 2). HSF1 phosphorylation at Ser-303 thus involves hierarchical phosphorylation with primary phosphorylation by MAPK preceding secondary modification by GSK3. A similar indirect mechanism was demonstrated previously in the phosphorylation of protein substrates by GSK3 (44-46). Consistent with previous experiments showing that transfection of activated Ras protein and MEK-1 represses the heat shock response and that dominant negative constructs of ERK1 are activating, our data suggest that HSF1 is repressed under growth conditions through the Ras-MAPK pathway by primary phosphorylation by MAPK, leading to secondary phosphorylation by GSK3 (20-24). In addition, the finding that overexpression of GSK3alpha or GSK3beta directly represses HSF1 suggests that a subpopulation of HSF1 molecules may be constitutively phosphorylated at Ser-307 and that HSF1 may be directly regulated by the GSK3 pathway as well as indirectly through the Ras-MAPK pathway (Figs. 2 and 3). GSK3alpha or GSK3beta is involved in transcriptional regulation and is regulated by a signaling pathway activated by cell surface receptors for the Wnt proteins and propagated through a kinase cascade involving phosphatidylinositol 3-kinase and protein kinase B (46-49). This process results in the inhibition of GSK3 activity, which is constitutive in noninduced conditions (48). Protein kinase B (also known as RAC-PK or Akt) is activated by heat shock and could potentially activate HSF1 through GSK3 inhibition (50). It is not clear whether one or both of the isoforms of GSK3 interact with HSF1 in vivo because both GSK3alpha and GSK3beta can phosphorylate HSF1 in vitro and repress HSF1 when expressed at high level in vivo (Figs. 1 and 2) (20, 33). It is also apparent that HSF1 repression by MEK-1 involves mechanisms in addition to priming HSF1 for GSK3 phosphorylation (Fig. 2). We therefore examined the role in HSF1 repression of a second residue phosphorylated by MAPK in vitro located at serine 363 within a MAPK consensus motif (Figs. 2 and 4). The analysis indicated, however, that Ser-363 is not involved in repression of HSF1 by the Ras-MAPK pathway, and in fact, Ser-363 mediates HSF1 repression by the PKC family (Figs. 5 and 6). PKCalpha and PKCzeta both strongly repressed HSF1 function, and repression was relieved by mutation of Ser-363 but not by mutation of Ser-303 (Figs. 5 and 6). The findings that PKC phosphorylates HSF1 in vitro, that this effect is inhibited by loss of Ser-363, and that the repressive effects of PKCalpha expression are reversed by either S363A mutation or calphostin C exposure suggest that PKCalpha represses HSF1 largely through direct enzymatic modification (Figs. 5-7). Previous studies suggested a potential role for PKC in the heat shock response based on findings that phorbol esters enhance HSF1-HSE binding and HSP synthesis during heat shock (51). Similar observations were made in our unpublished studies and are seemingly at odds with a role for PKC in HSF1 repression.3 However, in the NIH 3T3 cell line used here, exposure to the active phorbol ester phorbol myristate acetate (PMA) leads to a progressive down-regulation of PMA binding activity, reaching levels only 20% of controls by 8 h exposure to 10-7 M PMA.4 In addition, such treatment leads to functional loss of PKC activity, as indicated by the finding that long term treatment with PMA eliminates subsequent PMA-induced MAPK induction in these cells (40). Stimulatory effects of PMA on HSF1 activity may thus reflect the down-regulation of PMA-binding PKC species. In addition, PMA has been shown to increase the cellular levels of HSF1 and HSF1 mRNA (52). Effects of PMA on HSF1 activity may therefore also reflect alterations in HSF1 levels. However, our findings indicate that directly activating PKC by overexpression leads to HSF1 repression through phosphorylation on Ser-363 (Fig. 6). It is not clear, however, to what extent PKC is involved in HSF1 regulation under basal conditions. Treatment with calphostin C caused only a slight increase in HSF1 activity in NIH 3T3 cells (Fig. 6), although a larger (50%) increase was observed in HeLa cells (not shown). PKC may thus play a less prominent role, compared with MAPK in HSF1 repression during conditions of continuous growth (20). Repression through Ser-363 may be more significant in conditions leading to acute increases in PKC activity, such as the activation of serpentine receptors and binding of stimulatory ligands to growth factor receptors (38). It is apparent however, that the region in HSF1 containing Ser-363 is phosphorylated in cells in vivo, suggesting a potential role for Ser-363 in HSF1 regulation at 37 °C (20).

Repression by MAPK and GSK3 involves HSF1 phosphorylation at sites within the regulatory domain that control the activity of adjacent activation domains (42, 43). PKC repression is, however, exerted through a site (Ser-363) in a previously uncharacterized region of HSF1 between the regulatory domain (amino acids 220-310) and the C-terminal activation domains (amino acids 371-529) (42, 43). The close proximity of Ser-363 to activation domain 1 (amino acids 371-430) suggests a potential regulatory interaction (42, 43). Although we have not addressed here the role of phosphorylation in HSF1 activation by heat shock, these experiments suggest possible mechanisms. HSF1 activation by heat shock could involve antagonism of the mechanisms that repress HSF1 at 37 °C, an overriding regulatory change imposed by heat shock, or a combination of both mechanisms. That the reversal of negative regulation during heat shock is a potential mechanism for HSF1 activation is suggested by our findings that HSF1 overexpression in the absence of heat shock activates its function (Fig. 2) (10, 20, 30). These findings imply that the elevated HSF1 concentrations in transfectants titrate intracellular repressors and thus permit HSF1 activation at high concentrations. In addition, HSF1 mutants resistant to the inhibitory phosphorylations at Ser-303 and Ser-307 activate transcription at lower concentrations than those required for HSP70 promoter activation by wild-type HSF1, again suggesting the existence of titratable HSF1 inhibitors (20). However, our earlier studies suggested that HSF1 is phosphorylated in vivo on sites associated with HSF1 repression (Ser-303/307; peptide a) and Ser-363 (peptide b) before and after a heat shock (30 min at 42 °C) that activates HSP gene transcription (20). Thus, dephosphorylation of these residues may not be essential for HSF1 activation by heat shock. Therefore, although reversal of HSF1 repression may participate in activation, it seems likely that additional events unique to heat shock are involved in the full activation of HSF1 by heat, as discussed previously (17). A similar conclusion was reached in previous studies of the transcriptional regulatory domain of HSF1 showing that this domain has the property of dominantly repressing transcriptional activation domains at 37 °C and activating such domains during heat shock (43). The degree of transcriptional activation induced by heat shock exceeded the amount predicted to be caused by the reversal of repression (43).

In summary, therefore, HSF1 is a tightly regulated factor repressed at 37 °C by the action of protein kinase cascades terminating in the activation of MAPK, GSK3, and PKC, which lead to phosphorylation of inhibitory serine residues 307, 303, and 363. Coupling HSF1 repression to protein kinase activities associated with normal anabolic function may ensure suppression of HSF1 at 37 °C during growth and recovery from stress.

    ACKNOWLEDGEMENTS

We thank Dr. C. N. Coleman and the Associates of the Joint Center for Radiation Therapy for encouragement and support. We are grateful to Margaret Condron and David Teplow for peptide sequencing, to David Sachs for help and advice related to two-dimensional mapping, and to James Woodgett for discussions regarding GSK3. For advice regarding the transfection experiments, we thank Yue Xie and Changmin Chen.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants CA4707, CA31303, and CA50642.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Present address: Dept. of Biology, University of Massachusetts, Lowell, MA 01854.

These authors contributed equally to this work.

** To whom correspondence should be addressed: Dept. of Adult Oncology, Dana Farber Cancer Institute and Joint Center for Radiation Therapy, Harvard Medical School, 44 Binney St., Boston, MA 02115. Tel.: 617-632-3885; Fax: 617-632-4599; E-mail: stuart_calderwood{at}dfci.harvard.edu.

1 The abbreviations used are: HSP, heat shock protein; HSF, heat shock factor; HSE, heat shock element; GSK, glycogen synthase kinase; MAPK, mitogen-activated protein kinase; MAPKAP K2, MAPK-activated protein kinase 2; CAT, chloramphenicol acetyltransferase; PMA, phorbol myristate acetate; wt, wild-type; PKC, protein kinase C.

2 J. L. Bruce, C. Chen, Y. Xie, R. Zhong, M. A. Stevenson, and S. K. Calderwood, submitted for publication.

3 X. Zhang and S. K. Calderwood, unpublished data.

4 B. Farnum and S. K. Calderwood, unpublished data.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

  1. Lindquist, S., and Craig, E. A. (1988) Annu. Rev. Genet. 22, 631-637[CrossRef][Medline] [Order article via Infotrieve]
  2. Georgopolis, C., and Welch, W. J. (1993) Annu. Rev. Cell Biol. 9, 601-634[CrossRef]
  3. Wu, C. (1995) Annu. Rev. Cell Dev. Biol. 11, 441-469[CrossRef][Medline] [Order article via Infotrieve]
  4. Voellmy, R. (1994) Crit. Rev. Euk. Gene Expr. 4, 357-401[Medline] [Order article via Infotrieve]
  5. Morimoto, R. I. (1993) Science 269, 1409-1410
  6. Krebs, R. A., and Feder, M. E. (1997) Cell Stress Chaperones 2, 60-71[Medline] [Order article via Infotrieve]
  7. Marui, N., Nishimo, H., Sakai, T., Aoike, A., Kawai, K., and Fukushima, M. (1991) Biochem. Biophys. Res. Commun. 179, 1662-1669[Medline] [Order article via Infotrieve]
  8. Holbrook, N., Carlson, S. G., Choi, A. M. K., and Fargnoli, J. (1992) Mol. Cell. Biol. 12, 1528-1534[Abstract]
  9. Feder, J. H., Rossi, J. M., Soloman, J., Soloman, N., and Lindquist, S. (1992) Genes Dev. 6, 1402-1413[Abstract]
  10. Chen, C., Xie, Y., Stevenson, M. A., Auron, P. E., and Calderwood, S. K. (1997) J. Biol. Chem. 272, 26803-26806[Abstract/Free Full Text]
  11. Westwood, T., and Wu, C. (1993) Mol. Cell. Biol. 13, 3481-3486[Abstract]
  12. Rabindran, S. K., Haroun, R. I., Clos, J., Wisniewski, J., and Wu, C. (1993) Science 259, 230-234[Medline] [Order article via Infotrieve]
  13. Hensold, J. O., Hunt, C. R., Calderwood, S. K., Houseman, D. E., and Kingston, R. E. (1990) Mol. Cell. Biol. 10, 1600-1608[Medline] [Order article via Infotrieve]
  14. Price, B. D., and Calderwood, S. K. (1991) Mol. Cell. Biol. 11, 3365-3368[Medline] [Order article via Infotrieve]
  15. Bruce, J. L., Price, B. D., Coleman, C. N., and Calderwood, S. K. (1993) Cancer Res. 53, 12-15[Abstract]
  16. Cotto, J. J., Kline, M., and Morimoto, R. I. (1996) J. Biol. Chem. 271, 3355-3358[Abstract/Free Full Text]
  17. Xia, W., and Voellmy, R. (1997) J. Biol. Chem. 272, 4094-4102[Abstract/Free Full Text]
  18. Sorger, P. K., and Pelham, H. R. B. (1988) Cell 54, 855-864[Medline] [Order article via Infotrieve]
  19. Sarge, K. D., Murphy, S. P., and Morimoto, R. I. (1993) Mol. Cell. Biol. 13, 1392-1407[Abstract]
  20. Chu, B., Soncin, F., Price, B., D., Stevenson, M. A., and Calderwood, S. K. (1996) J. Biol. Chem. 271, 30847-30857[Abstract/Free Full Text]
  21. Engelberg, D., Zandi, E., Parker, C. S., and Karin, M. (1994) Mol. Cell. Biol. 14, 4929-4937[Abstract]
  22. Mivechi, M. F., and Giaccia, A. J. (1995) Cancer Res. 55, 5512-5519[Abstract]
  23. Knauf, U., Newton, E. M., Kyriakis, J., and Kingston, R. E. (1996) Genes Dev. 10, 2782-2793[Abstract]
  24. Kline, M. P., and Morimoto, R. I. (1997) Mol. Cell. Biol. 17, 2107-2115[Abstract]
  25. Rabindran, S. K., Gioorgi, G., Clos, J., and Wu, C. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 6906-6910[Abstract]
  26. Soncin, F., Prevelige, R., and Calderwood, S. K. (1997) Protein Expression Purif. 9, 27-32[CrossRef][Medline] [Order article via Infotrieve]
  27. Lane, H. A., and Thomas, G. (1991) Methods Enzymol. 200, 269-291
  28. Boyle, W. J., Van Der Geer, P., and Hunter, T. (1991) Methods Enzymol. 201, 110-149[Medline] [Order article via Infotrieve]
  29. Matsudaira, P. (1990) in Guide to Protein Purification (Deutscher, M. P., ed), pp. 602-613, Academic Press, San Diego
  30. Cahill, C. M., Waterman, W. R., Auron, P. E., and Calderwood, S. K. (1996) J. Biol. Chem. 271, 24874-24879[Free Full Text]
  31. Schiller, P., Amin, J., Ananthan, J., Brown, M. E., Scott, W. A., and Voellmy, R. (1988) J. Mol. Biol. 203, 97-105[Medline] [Order article via Infotrieve]
  32. Mansour, S. J., Matten, W. T., Hermann, A. S., Candia, J. M., Rong, S., Fukasawa, K., Vande Woude, G. F., and Ahn, N. G. (1994) Science 265, 966-970[Medline] [Order article via Infotrieve]
  33. Woodgett, J. R. (1991) Methods Enzymol. 201, 564-581
  34. Marshall, C. J. (1994) Curr. Opinion Genet. Dev. 4, 82-89[Medline] [Order article via Infotrieve]
  35. Herskowitz, I. (1995) Cell 80, 187-197[Medline] [Order article via Infotrieve]
  36. Kemp, B. E., and Pearson, R. B. (1991) Methods Enzymol. 201, 121-135
  37. Parker, P. J. (1994) in Protein Kinases (Woodgett, J. R., ed), pp. 68-84, Oxford University Press, Oxford
  38. Nishizuka, Y. (1992) Science 258, 607-614[Medline] [Order article via Infotrieve]
  39. Olivier, A. R., Kiley, S. C., Pears, P., Schaap, D., Jaken, S., and Parker, P. J. (1992) Biochem. Soc. Trans. 20, 603-607[Medline] [Order article via Infotrieve]
  40. Stevenson, M. A., Pollock, S. S., Coleman, C. N., and Calderwood, S. K. (1994) Cancer Res. 54, 12-15[Abstract]
  41. Tamaoki, T. (1991) Methods Enzymol. 201, 340-347[Medline] [Order article via Infotrieve]
  42. Green, M. T., Schuetz, T. J., Sullivan, E. K., and Kingston, R. E. (1995) Mol. Cell. Biol. 15, 3354-3362[Abstract]
  43. Newton, E. M., Knauf, U., Green, M., and Kingston, R. E. (1996) Mol. Cell. Biol. 16, 839-846[Abstract]
  44. Roach, P. J. (1991) J. Biol. Chem. 266, 14139-14142[Abstract/Free Full Text]
  45. Rubinfeld, B., Albert, I., Porfiri, E., C., F., Munemitsu, S., and Polakis, P. (1996) Science 272, 1023-1026[Abstract]
  46. Fiol, C. J., Williams, J. S., Chou, C. H., Wang, Q. M., Roach, P. J., and Andrisani, O. M. (1994) J. Biol. Chem. 269, 32187-32193[Abstract/Free Full Text]
  47. Nikilokaki, E., Coffer, P. J., Hemelsoet, R., Woodgett, J. R., and Defize, L. H. (1993) Oncogene 8, 833-840[Medline] [Order article via Infotrieve]
  48. Miller, J. R., and Moon, R. T. (1996) Genes Dev. 10, 2527-2539[CrossRef][Medline] [Order article via Infotrieve]
  49. Didichenko, S. A., Tilton, B., Hemmings, B. A., and Ballmer-Hofer, K. (1996) Curr. Biol. 6, 1271-1278[Medline] [Order article via Infotrieve]
  50. Konishi, H., Matsuzaki, H., Tanaka, M., Ono, Y., Tokunaga, C., Kurodo, S., and Kikkawa, U. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7639-7643[Abstract/Free Full Text]
  51. Holmberg, C. I., Leppa, S., Eriksson, J. E., and Sistonen, L. (1997) J. Biol. Chem. 272, 6792-6798[Abstract/Free Full Text]
  52. Ding, X. Z., Smallridge, R. C., Galloway, R. J., and Kiang, J. G. (1996) J. Invest. Med. 44, 144-153[Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.